Spherox

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
22-08-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
22-08-2023

Viambatanisho vya kazi:

spheroids of human autologous matrix-associated chondrocytes

Inapatikana kutoka:

CO.DON Gmbh

ATC kanuni:

M09AX02

INN (Jina la Kimataifa):

spheroids of human autologous matrix-associated chondrocytes

Kundi la matibabu:

Other drugs for disorders of the musculo-skeletal system

Eneo la matibabu:

Cartilage Diseases

Matibabu dalili:

Repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee (International Cartilage Repair Society [ICRS] grade III or IV) with defect sizes up to 10 cm2 in adults.,

Bidhaa muhtasari:

Revision: 8

Idhini hali ya:

Authorised

Idhini ya tarehe:

2017-07-10

Taarifa za kipeperushi

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SPHEROX 10-70 SPHEROIDS/CM
2 IMPLANTATION SUSPENSION
spheroids of human autologous matrix-associated chondrocytes
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN WITH THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor.
•
If you get any side effects, talk to your doctor or physical
therapist. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Spherox is and what it is used for
2.
What you need to know before you are given Spherox
3.
How to use Spherox
4.
Possible side effects
5.
How to store Spherox
6.
Contents of the pack and other information
1.
WHAT SPHEROX IS AND WHAT IT IS USED FOR
Spherox is a medicine used to
REPAIR DAMAGE TO THE CARTILAGE OF THE KNEE
in adults and in
adolescents whose bones in the joint have finished growing. Cartilage
is a hard smooth layer inside
your joints, on the ends of the bones. It protects the bones and
allows joints to work smoothly.
Spherox is used in adults, or adolescents whose bones have finished
growing, when the cartilage in the
knee joint is damaged, for example by acute injury, such as a fall or
long-term wear due to incorrect
weight bearing on the joint. Spherox is used to treat defects up to 10
cm² in size.
Spherox consists of so-called spheroids. A spheroid looks like a tiny
pearl made of cartilage cells and
cartilage material derived from your own body. To make the spheroids,
a small cartilage sample is
taken from one of your joints during a minor operation, and then grown
in the laboratory to make the
medicine. The spheroids are implanted by surgery to the damaged
cartilage area and stick to the
damaged part. They are then expected to repair the damage with healthy
and functional cartilage over
time.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN SPHEROX
DO NOT USE SPHEROX IF
•
the bones in the knee joi
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Spherox 10-70 spheroids/cm
2
implantation suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1
GENERAL DESCRIPTION
Spheroids of human autologous matrix-associated chondrocytes for
implantation suspended in isotonic
sodium chloride solution.
2.2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Spheroids are spherical aggregates of
_ex vivo_
expanded human autologous chondrocytes and self-
synthesized extracellular matrix.
Each pre-filled syringe or applicator contains a specific number of
spheroids according to the defect
size (10-70 spheroids/cm
2
) to be treated.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Implantation suspension.
White to yellowish spheroids of matrix-associated autologous
chondrocytes in a clear, colourless
solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Repair of symptomatic articular cartilage defects of the femoral
condyle and the patella of the knee
(International Cartilage Regeneration & Joint Preservation Society
[ICRS] grade III or IV) with defect
sizes up to 10 cm
2
in adults and adolescents with closed epiphyseal growth plate in the
affected joint.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Spherox is intended for autologous use only. It must be administered
by a specialised orthopedic
surgeon and in a medical facility.
Posology
10-70 spheroids are applied per square centimetre defect.
_Elderly _
The safety and efficacy of Spherox in patients aged over 50 years have
not been established. No data
are available.
_Paediatric population _
The safety and efficacy of Spherox in children and adolescents with
still open epiphyseal growth plate
in the affected joint have not been established. No data are
available.
3
Method of administration
For intraarticular use.
Spherox is administered to patients by intraarticular implantation.
The treatment with Spherox is a two-step procedure.
In a first step, a biopsy must be performed during a surgical
procedure (preferably an arthros
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kireno 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 14-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 22-08-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 22-08-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 22-08-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 22-08-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 14-07-2021

Tazama historia ya hati